Stock Evaluator: Elutia Inc. (ELUT)

Elutia Inc. ELUT

$0.85 -0.02 -1.81%
September 2, 2026 4:00:00 PM EST November 10, 2021 Volume: 9,451
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Commentary & Analysis


Financial Summary

Share Statistics ELUT Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $37.4 $288.9 13%
Shares Out (Mil) 44.2 54.0 44%
Institutional Ownership 80.0% 93.1% 49%
Float (Mil) 29.5 41.4 36%
Beta 0.88 0.94 52%
Avg Daily Volume (000s) 67 480 32%
Price Change
(52-week)
(61.0%) 59.9% 11%
Growth ELUT Industry
Median
Percentile
(All Stocks)
Sales (5yr) (22.0%) 14.1% 2%
Net Income (5yr) 34.8% (10.1%) 88%
EPS (5yr) 16.0% 15.9% 59
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (46.6%) (15.6%) 8%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials ELUT Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $12 $37 10%
Net Income (TTM) (Mil) $52 ($43) 55%
EPS (TTM) $1.202 ($1.500) 63%
Operating Cash Flow (TTM) (Mil) ($44) ($31) 10%
Net Cash Flow (TTM) (Mil) na $2 na
Long-Term Debt (Q1) (Mil) $4 $4 23%
Enterprise Value (Q1) (Mil) $24 $190 12%
Valuation ELUT Industry
Median
Percentile
(All Stocks)
P/B 2.35 2.84 56%
P/E na 20.0 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios ELUT Industry
Median
Percentile
(All Stocks)
Gross Margin 57.8% 66.9% 70%
Net Margin 426.9% (74.2%) 100%
ROA 133.7% (47.7%) 100%
ROE (397.0%) (55.0%) 2%
Liabilities to Assets 63.9% 29.6% 59%
F-Score 5 3 50%

Elutia Inc. did not pass any screens on 9/2/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors